CSI Market
Sign In | Register

Quantrx Biomedical (QTXB) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access QTXB Annual Cash Flow →
The cash flow figures below highlight longer-term patterns in how Quantrx Biomedical manages cash inflows and outflows over time.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Sep 30 2022)
9 Months 		(Jun 30 2022) (Mar 31 2022) (Dec 31 2021) (Sep 30 2021)
Operating Activities
Income-0.20
Depreciation & amortization0.00
Amortization of Other Assets0.00
Increase (Decrease) in Deferred Revenue0.00
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Increase (Decrease) in Inventories0.00
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property0.00
Share-based Compensation0.00
Noncash Contribution Expense0.00
Gains (Losses) on Extinguishment of Debt0.00
Noncash Fair Value Of Common Stock Issued As Settlement Of Accrued Payables-
Noncash Expense Related To Common Stock Issued As Compensation-
Noncash Fair Value Of Preferred Stock Issued As Compensation-
Noncash Gain On Preferred Stock Exchanged-
Noncash Expense Related To Common Stock Related To Notes Payable-
Net Gain On Settlement Of Accounts Payable-
Noncash Expense Related To Common Stock Issued With Notes Payable-
Noncash Expenses Related To Common Stock Warrants Issued For Consulting-
Gain On Settlement Of Accounts Payable-
Noncash Gain On Exchange Of Equity Investment-0.03
Debt Instrument Decrease Forgiveness0.06
Income taxes0.00
Gain (Loss) on Investments0.00
Increase (Decrease) in Accounts Receivable0.00
Increase (Decrease) in Accounts Payable0.01
Increase (Decrease) in Interest Payable, Net0.16
Increase (Decrease) in Security Deposits0.00
Increase (Decrease) in Prepaid Expense0.00
Other Working Capital0.00
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities0.00
Discontinued operations0.00
Net Cash flow from Operating Activities-0.03
Investing Activities
Capital Expenditures0.00
Sale of Capital Items0.00
Short-term Investments Proceeds0.00
Short-term Investments Acq.0.00
Real Estate Investments0.00
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities0.00
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.03
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock0.00
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net0.00
Net Cash Of Deconsolidated Subsidiary-
Noncash Gain Loss On Conversion Of Shares-
Settlement Of Notes Payable For Cash-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities0.03
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-0.03
Total Cash Flow0.00
4 historic quarters locked

Sign in to unlock the full Quantrx Biomedical cash flow history.

Sign In Create Free Account

About Quantrx Biomedical Corp Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001493152-22-031830

Figures are derived from filed reports and may be restated. Historical data is subject to revision.